BioLife Solutions (BLFS) Expected to Announce Quarterly Earnings on Thursday

BioLife Solutions (NASDAQ:BLFS) is expected to be posting its Q4 2025 results after the market closes on Thursday, February 26th. Analysts expect BioLife Solutions to post earnings of ($0.02) per share and revenue of $24.01 million for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 26, 2026 at 4:30 PM ET.

BioLife Solutions Stock Performance

BioLife Solutions stock opened at $22.65 on Wednesday. BioLife Solutions has a fifty-two week low of $19.10 and a fifty-two week high of $29.62. The firm has a market capitalization of $1.09 billion, a price-to-earnings ratio of -323.53 and a beta of 1.92. The stock’s fifty day moving average is $23.95 and its two-hundred day moving average is $25.23.

Analysts Set New Price Targets

BLFS has been the topic of a number of research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of BioLife Solutions in a research note on Wednesday, January 21st. Zacks Research raised shares of BioLife Solutions from a “hold” rating to a “strong-buy” rating in a report on Friday, January 23rd. Wall Street Zen lowered shares of BioLife Solutions from a “buy” rating to a “hold” rating in a research report on Sunday, November 30th. HC Wainwright restated a “buy” rating and set a $32.00 price objective on shares of BioLife Solutions in a research report on Monday, December 29th. Finally, UBS Group reaffirmed a “buy” rating on shares of BioLife Solutions in a research note on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, BioLife Solutions has a consensus rating of “Moderate Buy” and an average price target of $32.00.

Insider Buying and Selling

In other BioLife Solutions news, Director Amy Duross sold 2,000 shares of the stock in a transaction on Monday, December 15th. The stock was sold at an average price of $24.60, for a total transaction of $49,200.00. Following the transaction, the director owned 18,687 shares of the company’s stock, valued at $459,700.20. This represents a 9.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Troy Wichterman sold 30,000 shares of BioLife Solutions stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $25.72, for a total value of $771,600.00. Following the completion of the sale, the chief financial officer directly owned 152,769 shares of the company’s stock, valued at approximately $3,929,218.68. This represents a 16.41% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 37,802 shares of company stock valued at $967,191. Company insiders own 2.20% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of BLFS. T. Rowe Price Investment Management Inc. boosted its position in shares of BioLife Solutions by 27.4% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 5,180,824 shares of the medical equipment provider’s stock worth $125,273,000 after acquiring an additional 1,113,972 shares during the last quarter. Invesco Ltd. increased its position in BioLife Solutions by 9.2% during the fourth quarter. Invesco Ltd. now owns 3,932,191 shares of the medical equipment provider’s stock worth $95,080,000 after purchasing an additional 332,747 shares during the last quarter. XTX Topco Ltd raised its stake in BioLife Solutions by 280.4% during the fourth quarter. XTX Topco Ltd now owns 36,262 shares of the medical equipment provider’s stock worth $877,000 after purchasing an additional 26,729 shares during the period. SummitTX Capital L.P. acquired a new position in shares of BioLife Solutions in the 4th quarter valued at $1,747,000. Finally, Sandler Capital Management acquired a new position in shares of BioLife Solutions in the 4th quarter valued at $765,000. Institutional investors and hedge funds own 93.24% of the company’s stock.

About BioLife Solutions

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.